Zymeworks Inc.

ZYMENASDAQHealthcare● Active

$23.93

$-0.11(-0.46%)

Market Cap$1.8B

P/E Ratio—

52W High$29.75

52W Low$11.51

Avg Volume687K

Open$23.94

Beta1.14

Insider Trades Ownership Employees

Zymeworks Inc. (ZYME) Insider Trading

Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.

SEC EDGAR · FMP · ZYME · as of Jun 8, 2026

Activity summary

Buy transactions

P-Purchase only

Sell transactions

12 Months

Buy/Sell ratio

0.00

Buy/Sell (by trades)

Overall sentiment

BEARISH

↑ Buy 0%Active transactions only · RSU vesting excluded100% Sell ↓

Zymeworks Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only

As of Jun 8, 2026

ZYME insider buying and selling by quarter

ZYME insider selling · ZYME insider buying stocks · quarterly insider activity

Total insider buying (incl. awards)Total insider selling

5.7M2.9M0

2024 Q3

2024 Q4

2025 Q1

2025 Q2

2025 Q3

2025 Q4

2026 Q1

2026 Q2

Mobile shows last 4Q · Desktop shows full 8Q

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters

As of Jun 8, 2026

Active insiders

Most active in past 12 months · ZYME ceo insider trading

Showing all insiders · Click a card to filter the transactions table below

▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API

Recent insider transactions

ZYME executive sell shares · ZYME board member insider trading · ZYME insider trading SEC filing

Showing 26 most recent · Common Stock · Form 4 only

Scroll horizontally to see all columns

Date	Insider	Type	Shares	Price	Value	After trans.	Filing
Jan 12, 2026	Hollywood Mark EVP & Chief Operating Officer	Option	17,666	—	—	139,033	Form 4
Jan 12, 2026	Hollywood Mark EVP & Chief Operating Officer	Sale	6,120	$22.67	$139K	132,913	Form 4
Jan 12, 2026	Smith Jeffrey T L EVP & Chief Medical Officer	Option	17,666	—	—	36,018	Form 4
Jan 12, 2026	Smith Jeffrey T L EVP & Chief Medical Officer	Sale	9,310	$22.67	$211K	26,708	Form 4
Jan 12, 2026	Moore Paul Andrew Chief Scientific Officer	Option	17,666	—	—	58,057	Form 4
Jan 12, 2026	Moore Paul Andrew Chief Scientific Officer	Sale	9,560	$22.67	$217K	48,497	Form 4
Jan 12, 2026	Galbraith Kenneth Chair & CEO · Director	Option	64,000	—	—	257,266	Form 4
Jan 12, 2026	Galbraith Kenneth Chair & CEO · Director	Sale	30,424	$22.67	$690K	226,842	Form 4
Jan 6, 2026	PATTERSON LEONE D EVP, Chief Bus & Fin Officer	Award	459	$10.55	$5K	459	Form 4
Jan 5, 2026	Smith Jeffrey T L EVP & Chief Medical Officer	Option	20,000	—	—	28,890	Form 4
Jan 5, 2026	Smith Jeffrey T L EVP & Chief Medical Officer	Sale	10,538	$25.10	$264K	18,352	Form 4
Jan 5, 2026	Galbraith Kenneth Chair & CEO · Director	Option	66,666	—	—	224,952	Form 4
Jan 5, 2026	Galbraith Kenneth Chair & CEO · Director	Sale	31,686	$25.10	$795K	193,266	Form 4
Jan 5, 2026	Galbraith Kenneth Chair & CEO · Director	Option	47,668	—	—	180,943	Form 4
Jan 5, 2026	Galbraith Kenneth Chair & CEO · Director	Sale	22,657	$25.10	$569K	158,286	Form 4
Jan 5, 2026	Moore Paul Andrew Chief Scientific Officer	Option	20,000	—	—	51,212	Form 4
Jan 5, 2026	Moore Paul Andrew Chief Scientific Officer	Option	17,168	—	—	40,501	Form 4
Jan 5, 2026	Moore Paul Andrew Chief Scientific Officer	Sale	10,821	$25.10	$272K	40,391	Form 4
Jan 5, 2026	Moore Paul Andrew Chief Scientific Officer	Sale	9,289	$25.10	$233K	31,212	Form 4
Dec 22, 2025	Galbraith Kenneth Chair & CEO · Director	Option	100,000	—	—	180,803	Form 4
Dec 22, 2025	Galbraith Kenneth Chair & CEO · Director	Sale	47,528	$27.02	$1.28M⚡	133,275	Form 4
Aug 12, 2025	Ciongoli Gregory Austin Director	Award	415,000	$12.02	$4.99M⚡	488,500	Form 4
Jun 26, 2025	EcoR1 Capital, LLC Director	Other	5,086,480	$0.00	$509	22,970,388	Form 4
Jun 26, 2025	EcoR1 Capital, LLC Director	Other	41	$12.71	$521	22,970,388	Form 4
May 19, 2025	EcoR1 Capital, LLC Director	Purchase	5,919	$11.78	$70K	17,883,908	Form 4

Hollywood Mark

EVP & Chief Operating Officer

Option

Date

Jan 12

17,666

Price

—

Value

—

View Form 4 on SEC.gov

Hollywood Mark

EVP & Chief Operating Officer

Sale

Date

Jan 12

6,120

Price

$22.67

Value

$139K

View Form 4 on SEC.gov

Smith Jeffrey T L

EVP & Chief Medical Officer

Option

Date

Jan 12

17,666

Price

—

Value

—

View Form 4 on SEC.gov

Smith Jeffrey T L

EVP & Chief Medical Officer

Sale

Date

Jan 12

9,310

Price

$22.67

Value

$211K

View Form 4 on SEC.gov

Moore Paul Andrew

Chief Scientific Officer

Option

Date

Jan 12

17,666

Price

—

Value

—

View Form 4 on SEC.gov

Moore Paul Andrew

Chief Scientific Officer

Sale

Date

Jan 12

9,560

Price

$22.67

Value

$217K

View Form 4 on SEC.gov

Galbraith Kenneth

Chair & CEO · Director

Option

Date

Jan 12

64,000

Price

—

Value

—

View Form 4 on SEC.gov

Galbraith Kenneth

Chair & CEO · Director

Sale

Date

Jan 12

30,424

Price

$22.67

Value

$690K

View Form 4 on SEC.gov

PATTERSON LEONE D

EVP, Chief Bus & Fin Officer

Award

Date

Jan 6

459

Price

$10.55

Value

$5K

View Form 4 on SEC.gov

Smith Jeffrey T L

EVP & Chief Medical Officer

Option

Date

Jan 5

20,000

Price

—

Value

—

View Form 4 on SEC.gov

Smith Jeffrey T L

EVP & Chief Medical Officer

Sale

Date

Jan 5

10,538

Price

$25.10

Value

$264K

View Form 4 on SEC.gov

Galbraith Kenneth

Chair & CEO · Director

Option

Date

Jan 5

66,666

Price

—

Value

—

View Form 4 on SEC.gov

Galbraith Kenneth

Chair & CEO · Director

Sale

Date

Jan 5

31,686

Price

$25.10

Value

$795K

View Form 4 on SEC.gov

Galbraith Kenneth

Chair & CEO · Director

Option

Date

Jan 5

47,668

Price

—

Value

—

View Form 4 on SEC.gov

Galbraith Kenneth

Chair & CEO · Director

Sale

Date

Jan 5

22,657

Price

$25.10

Value

$569K

View Form 4 on SEC.gov

Moore Paul Andrew

Chief Scientific Officer

Option

Date

Jan 5

20,000

Price

—

Value

—

View Form 4 on SEC.gov

Moore Paul Andrew

Chief Scientific Officer

Option

Date

Jan 5

17,168

Price

—

Value

—

View Form 4 on SEC.gov

Moore Paul Andrew

Chief Scientific Officer

Sale

Date

Jan 5

10,821

Price

$25.10

Value

$272K

View Form 4 on SEC.gov

Moore Paul Andrew

Chief Scientific Officer

Sale

Date

Jan 5

9,289

Price

$25.10

Value

$233K

View Form 4 on SEC.gov

Galbraith Kenneth

Chair & CEO · Director

Option

Date

Dec 22

100,000

Price

—

Value

—

View Form 4 on SEC.gov

Galbraith Kenneth

Chair & CEO · Director

Sale

Date

Dec 22

47,528

Price

$27.02

Value

$1.28M ⚡

View Form 4 on SEC.gov

Ciongoli Gregory Austin

Director

Award

Date

Aug 12

415,000

Price

$12.02

Value

$4.99M ⚡

View Form 4 on SEC.gov

EcoR1 Capital, LLC

Director

Other

Date

Jun 26

5,086,480

Price

$0.00

Value

$509

View Form 4 on SEC.gov

EcoR1 Capital, LLC

Director

Other

Date

Jun 26

Price

$12.71

Value

$521

View Form 4 on SEC.gov

EcoR1 Capital, LLC

Director

Purchase

Date

May 19

5,919

Price

$11.78

Value

$70K

View Form 4 on SEC.gov

⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar

1 / 2

▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —

About ZYME insider trading

ZYME insider trades

Zymeworks Inc. (ZYME) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Galbraith Kenneth (Chair & CEO · Director), Moore Paul Andrew (Chief Scientific Officer), Smith Jeffrey T L (EVP & Chief Medical Officer). Over the past 12 months, 5 insiders have filed transactions with the SEC. ZYME insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.

For Zymeworks Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →

Buy/Sell signal logic

acquisitionOrDisposition field:

A = Acquisition (buy) · D = Disposition (sell)

RSU vesting (M-Exempt) excluded from sentiment

Form 4SEC filing required within 2 business days of any insider transaction

10b5-1Pre-scheduled trading plan that allows insiders to sell on autopilot

Open MktDirect purchase or sale on the open market (excludes awards, options)

Ownership SEC filings Financial statements Price history Forecast & ratings Earnings

Frequently asked questions

ZYME insider trading · 5 questions

The insiders of Zymeworks Inc. (ZYME) include executives and directors such as Galbraith Kenneth (Chair & CEO · Director), Moore Paul Andrew (Chief Scientific Officer), Smith Jeffrey T L (EVP & Chief Medical Officer), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.

ZYME board member insider tradingwho are ZYME insidersZYME insider rosterZymeworks Inc. executives insider activity

▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026